Galectin-3

Galectin-3 Molekülinformation

Englischer Name	Galectin-3	Anzahl der inverkehr gebrachten Arzneimittel	1
Anzahl der klinischen Arzneimittel	7	Target-Alias	Galactoside-binding protein，GALBP，Epididymis Secretory Sperm Binding Protein，MAC2，Laminin-binding protein，CBP 35，Gal-3，IgE-binding protein，Carbohydrate-binding protein 35，L-31，Lectin L-29，LGALS3，Advanced Glycation End-Product Receptor 3，Lectin， Galactoside-Binding， Soluble， 3，Galactose-Specific Lectin 3，35 KDa Lectin，Mac-2 Antigen，Galectin-3，LGALS2，CBP35，GALIG，GAL3，L31，Galectin 3，MAC-2
Höchste Forschungs- und Entwicklungsphase	Approved

Englischer Name	Galectin-3
Target-Alias	Galactoside-binding protein，GALBP，Epididymis Secretory Sperm Binding Protein，MAC2，Laminin-binding protein，CBP 35，Gal-3，IgE-binding protein，Carbohydrate-binding protein 35，L-31，Lectin L-29，LGALS3，Advanced Glycation End-Product Receptor 3，Lectin， Galactoside-Binding， Soluble， 3，Galactose-Specific Lectin 3，35 KDa Lectin，Mac-2 Antigen，Galectin-3，LGALS2，CBP35，GALIG，GAL3，L31，Galectin 3，MAC-2
Anzahl der inverkehr gebrachten Arzneimittel	1
Anzahl der klinischen Arzneimittel	7
Höchste Forschungs- und Entwicklungsphase	Approved

Galectin-3 Produktliste

Attribut
Protein (3)
Produktbibliothek
Online (3)
Spezies
Human (3)
Etikett
His Tag (2)His Tag & Avi Tag (1)
Marker
Unconjugated (2)Biotin-labeled (1)

Produktnummer	Spezies	Expressionssystem	Produktbeschreibung	Vorbestellen/Bestellen
GA3-H5129	Human	E. coli	Human Galectin-3 Protein, His Tag	In den Warenkorb legen
GA3-H5247	Human	HEK293	Human Galectin-3 Protein, His Tag	In den Warenkorb legen
GA3-H82E3	Human	HEK293	Biotinylated Human Galectin-3 Protein, His,Avitag™	In den Warenkorb legen

Gesamtmenge3

Produktanfrage

Galectin-3 Molekülhintergrund

Galectin-3 (Gal-3) is also known as LGALS3, 35 kDa lectin, Carbohydrate-binding protein 35 (CBP 35), Galactose-specific lectin 3, Galactoside-binding protein (GALBP), IgE-binding protein, Laminin-binding protein, Mac-2 antigen, Lectin L-29. Galectin-3 is a member of the lectin family. LGALS3 / Galectin-3 is expressed in the nucleus, cytoplasm, mitochondrion, cell surface, and extracellular space. LGALS3 / Galectin-3 has been shown to be involved in the following biological processes: cell adhesion, cell activation and chemoattraction, cell growth and differentiation, cell cycle, and apoptosis.

Galectin-3 Molekülalias

Galectin-3,LGALS3,MAC2,Gal-3,35 kDa lectin,CBP 35,GALBP,IgE-binding protein,L-31,Laminin-binding protein,Lectin L-29,Mac-2 antigen

Klinische Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Indikationen	Klinische Studie
Olitigaltin	GB-0139; TD-139	Phase 2 Clinical	Lund University Foundation, The University Of Edinburgh	Coronavirus Disease 2019 (COVID-19); Idiopathic Pulmonary Fibrosis	Details
Galactomannan C	GM-CT-01	Phase 2 Clinical	Galectin Therapeutics Inc	Bile Duct Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Coronavirus Disease 2019 (COVID-19); Gallbladder Neoplasms; Head and Neck Neoplasms; Lung Neoplasms; Melanoma; Prostatic Neoplasms	Details
Selvigaltin	GB-1211; GB1211	Phase 2 Clinical	Galecto Inc	Carcinoma, Non-Small-Cell Lung; Hepatic Insufficiency; Melanoma; Metabolic Dysfunction-Associated Steatotic Liver Disease; Multiple Myeloma; Squamous Cell Carcinoma of Head and Neck	Details
ProLectin-M		Phase 2 Clinical	BioXyTran Inc	Coronavirus Disease 2019 (COVID-19); Cytokine Release Syndrome; Influenza, Human	Details
Gal-400	Gal-400	Phase 1 Clinical	Galecto Inc	Liver Cirrhosis; Metabolic Dysfunction-Associated Steatotic Liver Disease	Details
Belapectin	GR-MD-02	Phase 1 Clinical	Galectin Therapeutics Inc	Carcinoma, Non-Small-Cell Lung; Esophageal and Gastric Varices; Hepatic Insufficiency; Hypertension, Portal; Liver Cirrhosis; Melanoma; Metabolic Dysfunction-Associated Steatotic Liver Disease; Psoriasis; Squamous Cell Carcinoma of Head and Neck	Details
SIF-001	SIF001	Phase 1 Clinical	Suninflam Inc	Epilepsy; Neuroinflammatory Diseases	Details

Inverkehr gebrachte Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Frühestes Markenname	Frühestes Genehmigungsland	Früheste Indikation	Früheste Genehmigungsgesellschaft	Früheste Genehmigungsdatum	Indikationen	Klinische Studie
Ocriplasmin	A-01016; THR-409	Approved	Thrombogenics	Jetrea, Jejetrea	United States	Vitreomacular Adhesion	Thrombogenics Inc	2012-10-17	Arterial Occlusive Diseases; Diabetic macular oedema; Diabetic Retinopathy; Disease Progression; Eye Diseases; Macular Degeneration; Retinal Diseases; Retinal Vein Occlusion; Stroke; Uveitis; Venous Thrombosis; Vitreomacular Adhesion; Vitreous Detachment	Details